HepaRegeniX is backed by experienced life science investors, including Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund (BIVF), Coparion, High-Tech Gründerfonds, Ascenion ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

A new Tufts University study finds that not getting enough vitamin K, found in leafy greens like spinach and kale, could harm ...